Australian pharma company De Motu Cordis (DMC), which is developing an epinephrine DPI for the treatment of anaphylaxis, announced that it has contracted with Catalent for product assembly, expanding a November 2022 deal with the CDMO that covered formulation and manufacturing. The extension of the deal will provide manufacturing and assembly services through a potential commercial launch, the company says.
According to DMC, several clinical trials of DMC-IH1 inhaled dry powder epinephrine have been completed in Australia, and the inhaler is in pre-clinical development in the US, with most of the $21 million the company has raised so far for development of the DPI coming from “the Queensland Business Development Fund, high net worth individuals and Australian family offices.” A Series A financing round is planned for the first half of next year.
DMC CEO Peter O’Neill commented, “We are excited to build on our partnership with Catalent, one of the world’s leading CDMOs, and look forward to Catalent’s team supporting our ability to further advance DMC-IH1, through support for drug product manufacture and dry powder inhaler assembly. Catalent provides DMC with a consistency of quality and manufacturing excellence in the United States to service global markets.”
Read the De Motu Cordis press release.
